-
Mashup Score: 0
Dabrafenib plus trametinib can produce durable responses in pediatric patients with relapsed or refractory, BRAFV600-mutant high-grade glioma, a phase 2 trial suggests.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2JNCCN 360 - Hepatobiliary - Researchers Use Genomics to Inform the Creation of New Model for Pediatric Hepatoblastoma - 9 month(s) ago
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers Use Genomics to Inform the Creation of New Model for Pediatric #Hepatoblastoma: https://t.co/lHOcF5Q0qn #JNCCN360 #HPBCSM #pedonc https://t.co/Eaapfhv7lH
-
-
Mashup Score: 0
A study of adolescents and young adults with cancer demonstrated the importance of the spiritual dimension to the patients’ experience of cancer.
Source: www.oncologynurseadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a recent study of AYAs with cancer, researchers noted apparent increases in these patients connecting with their spirituality after a cancer diagnosis. Reported in the @oncologynursing. https://t.co/0WRGdMzgZc #PedOnc #CancerCare
-
-
Mashup Score: 0John Laszlo’s dual role: (1) Working to cure childhood leukemia, and (2) Writing the authoritative book on it - 9 month(s) ago
His father, Daniel Laszlo, did early work on folate antagonists When John Laszlo joined the Acute Leukemia Service at NCI in 1956, the field of oncology was nascent—and the cure for childhood leuke
Source: cancerhistoryproject.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
John Laszlo’s dual role: (1) Working to cure childhood leukemia, and (2) Writing the authoritative book on it. #PedOnc #HemOnc https://t.co/wLiv07r6NE
-
-
Mashup Score: 0Specialized Care Needed for LGBTQ+ AYAs With Cancer - 9 month(s) ago
LGBTQ+ adolescents and young adults with cancer face unique challenges in the health care setting, a review suggests.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
AYAs with cancer who are sexual or gender minorities face unique challenges in the health care setting. Presented in a poster at @ASCO #ASCObt23. https://t.co/TuZvIbjE6x #PedOnc #CancerCare
-
-
Mashup Score: 1Outcomes in Pediatric ALL With Prolonged Therapy for IKZF1 Deletion and Reduced Therapy for Other Risk Groups - The ASCO Post - 9 month(s) ago
By Matthew Stenger Posted: 7/28/2023 10:50:00 AM Last Updated: 7/28/2023 9:57:37 AM In a recent study (Dutch Childhood Oncology Group [DCOG] ALL11) reported in the Journal of Clinical Oncology, Pieters et al found that modifications in therapy appeared to improve outcomes and reduce drug exposure in…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Outcomes in Pediatric ALL With Prolonged Therapy for IKZF1 Deletion and Reduced Therapy for Other Risk Groups https://t.co/h4BfaRSo3b #leusm #leukemia #pedonc #hematology
-
-
Mashup Score: 0Polygenic Risk Score and Chemotherapy-Related Subsequent Malignant Neoplasms in Childhood Cancer Survivors - The ASCO Post - 9 month(s) ago
In a study reported in the Journal of Clinical Oncology, Im et al found that a polygenic risk score (PRS) may be useful in stratifying risk for subsequent malignant neoplasms among nonirradiated survivors of childhood cancer according to chemotherapy received. The study involved evaluation of subsequent malignant neoplasms among long-term childhood cancer survivors of European (n = 9,895) and African (n = 718) genetic ancestry from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Polygenic Risk Score and Chemotherapy-Related Subsequent Malignant Neoplasms in Childhood Cancer Survivors https://t.co/rWSWn7djYQ #survivorship #pedonc #screening
-
-
Mashup Score: 0
A polygenic risk score can predict the risk of second malignant neoplasms in pediatric cancer survivors who were treated with chemotherapy, according to researchers.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A polygenic risk score can predict the risk of second malignant neoplasms in #pediatricCancer survivors who were treated with chemotherapy. Published in @JCO_ASCO. https://t.co/AepaNLfLik #PedOnc #CancerSurvivors
-
-
Mashup Score: 0Pediatric Early Warning Systems Implementation in Resource-Limited Latin American Hospitals - The ASCO Post - 10 month(s) ago
In a study reported in The Lancet Oncology, Agulnik et al found that implementation of pediatric early warning systems resulted in reduced clinical deterioration event mortality among children with cancer in resource-limited hospitals in Latin America. The Proyecto Escala de Valoración de Alerta Temprana (Proyecto EVAT) is a quality improvement collaborative to implement pediatric early warning systems in hospitals providing childhood cancer care. The current study included 32 resource-limited hospitals
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Implementation of Pediatric Early Warning Systems in Resource-Limited Latin American Hospitals https://t.co/EBv5zXHQyg #pedonc #oncology
-
-
Mashup Score: 0
Researchers have used a geriatric rating scale to show that childhood cancer survivors experience accelerated aging and have a higher risk of premature death than the general population.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers have used a geriatric rating scale to show that #childhoodcancer survivors experience accelerated aging and have a higher risk of premature death than the general population. Published in @JCO_ASCO. https://t.co/HBR0uOLOyq #PedOnc
-
The combination of dabrafenib and trametinib can produce durable responses in pediatric patients with R/R, BRAFV600-mutant high-grade #glioma. Published in @JCO_ASCO. https://t.co/1CuOGji3V0 #PedOnc #BrainCancer